Galectin Therapeutics
GALT
46 hedge funds and large institutions have $3.43M invested in Galectin Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 13 closing their positions.
10% less funds holding
Funds holding: 51 → 46 (-5)
14% less call options, than puts
Call options by funds: $130K | Put options by funds: $152K
33% less capital invested
Capital invested by funds: $5.14M → $3.43M (-$1.71M)
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
+$231K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$179K |
| 3 |
BCA
Benchmark Capital Advisors
New York
|
+$104K |
| 4 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$59.3K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
+$51.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.02M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$89K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$85.7K |
| 4 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$85K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$44K |
GALT Hedge Fund Activity: Q3 2016 in Review
46 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2016, worth a combined $3.43M — down 33% from $5.14M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GALT and 8 opened new positions — a net loss of 5 holders — while 13 trimmed existing stakes and 8 added.
The largest buyer was Courage Capital Management, opening a new position worth an estimated $231K. The largest seller was Sabby Management, cutting an estimated $1.02M.
- 46 institutional investors held Galectin Therapeutics (GALT) as of Q3 2016, down from 51 in Q2 2016.
- Funds reported $3.43M of Galectin Therapeutics stock for Q3 2016, down 33% quarter-over-quarter.
- 8 funds opened new Galectin Therapeutics positions in Q3 2016 and 13 closed out, a net change of -5 holders.
- The largest Galectin Therapeutics buyer in Q3 2016 was Courage Capital Management, an estimated $231K added.
- The largest Galectin Therapeutics seller in Q3 2016 was Sabby Management, an estimated $1.02M sold.
Based on aggregated 13F filings for Q3 2016.